Lilly plans expansion of local insulin plant

Eli Lilly and Co. will expand its Indianapolis manufacturing operations for the first time in more than two decades, the company announced Tuesday.

The Indianapolis-based drugmaker said the "multi-million" expansion will allow the plant to make insulin cartridges to meet what it describes as growing demand in the United States.

Lilly did not offer details about the expansion or say whether it  include new jobs.

U.S. sales of Lilly’s insulins, Humalog and Humulin, fell in Lilly’s most recent quarter by 2 percent and 7 percent, respectively. Lilly officials said the products were losing market share in the first half of the year after a large third-party payer removed Lilly’s insulins from its formulary.

Also, a contract Lilly had with Wal-Mart Stores Inc. to supply insulin for its ReliOn brand was terminated.
 

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}